24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
Spotlight
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Copaxone
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
teram of use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
11:25
“We're too slow in the adoption of AI technologies in healthcare”
10:21
“I lost something that was never truly mine”: The rise and fall of a billionaire
09:14
Turpaz sets sights on $200 million Japan acquisition as it accelerates global expansion
21:53
Iron Beam and Iron Dome at the frontlines of a quiet Israel-UAE alliance
More stories
Buzz
Most popular
Daily
Weekly
1
Cisco acquires AI security startup Astrix for $400 million
2
Five bidders advance in Nice’s $2.5 billion Actimize sale process
3
The 50 most promising Israeli startups - 2026
4
Israeli tech veterans launch $100 million AI and cyber fund
5
Israeli startup bets on psychedelic mushrooms for mental health treatment
More news
Copaxone
4 stories about Copaxone
Teva’s Stock Drops After Approval of Copaxone Competitors
08.10.17
|
Lilach Baumer
A day after Mylan announced FDA approval for its generic versions of Copaxone, drug companies Synthon and Alvogen announce European approval for their 40 mg/ml generic versions of Teva's blockbuster drug
Teva Loses Copaxone Market Exclusivity
04.10.17
|
Lilach Baumer
Rival Mylan received FDA approval for its generic versions of Copaxone, Teva’s flagship drug
New CEO to Break Teva’s Copaxone Habit
11.09.17
|
Sophie Shulman, Dror Reich
Troubled drugmaker says new CEO must work to quickly regain its financial credibility
With Bloated Debt, Teva Looks to Sell Assets
10.08.17
|
Eli Shimony and Gil Kalian
The generic drugmaker said it is looking to sell Medis, an Iceland-based company it bought in 2016
Previous Articles